Dermatologic Surgery

Special Issue of Dermatologic Surgery on Use of Botulinum Toxin
pp. 443-443(1)

Development of the Facial Lines Treatment Satisfaction Questionnaire and Initial Results for Botulinum Toxin Type A–Treated Patients
pp. 444-449(6)
Authors: Cox S.E.; Finn J.C.; Stetler L.; Mackowiak J.; Kowalski J.W.

Social Implications of Hyperfunctional Facial Lines
pp. 450-455(6)
Authors: Charles Finn J.; Cox S.E.; Earl M.L.

Satisfaction of Patients After Treatment With Botulinum Toxin for Dynamic Facial Lines
pp. 456-460(5)
Authors: Sommer B.; Zschocke I.; Bergfeld D.; Sattler G.; Augustin M.

A Prospective, Double-Blind, Randomized, Parallel- Group, Dose-Ranging Study of Botulinum Toxin Type A in Female Subjects With Horizontal Forehead Rhytides
pp. 461-467(7)
Authors: Carruthers A.; Carruthers J.; Cohen J.

Aesthetic Botulinum A Toxin in the Mid and Lower Face and Neck
pp. 468-476(9)
Authors: Carruthers J.; Carruthers A.

Botulinum Toxin Type A Treatment for Contouring of the Lower Face
pp. 477-483(7)
Authors: Park M.Y.; Ahn K.Y.; Jung D.S.

Effects of Botulinum Toxin Type A on Bilateral Masseteric Hypertrophy Evaluated With Computed Tomographic Measurement
pp. 484-489(6)
Authors: Kim H.J.; Yum K-W.; Lee S-S.; Heo M-S.; Seo K.

Botulinum Toxin A Treatment of Perioral Rhytides
pp. 490-495(6)
Authors: Semchyshyn N.; Sengelmann R.D.

Botulinum Toxin Type B (Myobloc)
pp. 496-500(5)
Authors: Baumann L.; Black L.

Prospective Open-Label Study of Botulinum Toxin Type B (Myobloc) at Doses of 2,400 and 3,000 U for the Treatment of Glabellar Wrinkles
pp. 501-507(7)
Author: Sadick N.S.

A Double-Blinded, Randomized, Placebo-Controlled Pilot Study of the Safety and Efficacy of Myobloc (Botulinum Toxin Type B)-Purified Neurotoxin Complex for the Treatment of Crow's Feet: A Double-Blinded, Placebo-Controlled Trial
pp. 508-515(8)
Authors: Baumann L.; Slezinger A.; Vujevich J.; Halem M.; Bryde J.; Black L.; Duncan R.

Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A
pp. 516-518(3)
Authors: Alster T.S.; Lupton J.R.

Botulinum Toxin Type B (MYOBLOC) Versus Botulinum Toxin Type A (BOTOX) Frontalis Study: Rate of Onset and Radius of Diffusion
pp. 519-522(4)
Authors: Flynn T.C.; Clark R.E.

Multicenter, Double-Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before Application
pp. 523-529(7)
Authors: Hexsel D.M.; de Almeida A.T.; Rutowitsch M.; de Castro I.A.; Silveira V.L.B.; Gobatto D.O.; Zechmeister M.; Mazzuco R.; Zechmeister D.

Foam During Reconstitution Does Not Affect the Potency of Botulinum Toxin Type A
pp. 530-532(3)
Authors: Trindade de Almeida A.R.; Kadunc B.V.; di Chiacchio N.; Neto D.R.

Diffusion and Short-Term Efficacy of Botulinum Toxin A After the Addition of Hyaluronidase and Its Possible Application for the Treatment of Axillary Hyperhidrosis
pp. 533-538(6)
Author: Goodman G.

Deep Resting Glabellar Rhytides Respond to BTX-A and Hylan B
pp. 539-544(6)
Authors: Carruthers J.; Carruthers A.; Maberley D.

Botulinum Toxin Type A in the Treatment of Bilateral Primary Axillary Hyperhidrosis: Efficacy and Duration With Repeated Treatments
pp. 545-548(4)
Authors: Lowe P.L.; Cerdan-Sanz S.; Lowe N.J.

Complications, Adverse Reactions, and Insights With the Use of Botulinum Toxin
pp. 549-556(8)
Author: Klein A.W.

Multiple Eccrine Hidrocystomas: A New Therapeutic Option With Botulinum Toxin
pp. 557-559(3)
Authors: Blugerman G.; Schavelzon D.; D'Angelo S.

Festoon Formation After Infraorbital Botulinum A Toxin: A Case Report
pp. 560-561(2)
Author: Goldman M.P.

Metallic Taste: An Unusual Reaction to Botulinum Toxin A
pp. 562-563(2)
Authors: Murray C.; Solish N.